SWOT ANALYSISSTRENGTHS

EXISTING CUSTOMER BASEADDED ADVANTAGE OF

CYCLODEXTRINNEW TECHNOLOGY - PULSATILE

RELEASEREDUCTION IN SIDE EFFECTS

WEAKNESSHIGH PRODUCTION COST

NEW COMPANY SO NOT KNOWN IN THE MARKET

OPPORTUNITIESMOLECULE IN THE GROWTH

STAGE OF THE PLCTOTAL MAKET SIZE 396 cr –

GROWING AT 47%SHIFT IN DISEASE PATTERN

THREATSTOO MANY TELMISARTAN BRANDS IN

THE MARKETCOMPETION FROM OTHER

MOLECULES SPECIALLY OLMESARTANSTRONG HOLD OF GLENMARK, CIPLA, LUPIN, DR REDDY’S IN THE MARKET

2010.5 2011 2011.5 2012 2012.5 2013 2013.5 2014 2014.50

1

2

3

4

5

6

7

8

Projected Sales(CR)

Projected Sales(CR)